Download PDF

1. Company Snapshot

1.a. Company Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics.


It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate.Novavax, Inc.was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Show Full description

1.b. Last Insights on NVAX

Novavax's recent performance was negatively impacted by the decline in COVID-19 vaccine sales, partly due to the sale of its Czech Republic manufacturing unit to Novo Nordisk for $200 million. The company's Q4 loss narrowed, but sales beat estimates, with $88.31 million in revenue, compared to $291 million a year ago. The decrease in product sales under APA agreements contributed to the decline. Additionally, the HHS Secretary's concerns regarding the efficacy of Novavax's protein-based COVID-19 vaccine in a recent interview may have weighed on investor sentiment.

1.c. Company Highlights

2. Novavax's Q4 and Full-Year 2025 Earnings: A Strong Performance

Novavax reported a significant increase in revenue for the full year 2025, with total revenue reaching $1.1 billion, a 65% increase year-over-year. The company's EPS came in at $0.11, beating estimates of -$0.66. The combined R&D and G&A expenses decreased by 53% for the full year 2025. The company's cash and accounts receivables stood at $857 million at the end of 2025, and an additional $80 million of nondilutive cash was added in the first quarter of 2026.

Publication Date: Mar -08

📋 Highlights
  • Revenue Surge:: Total revenue reached $1.1 billion in 2025, a 65% increase year-over-year, driven by partnerships and product sales.
  • Partnership Milestones:: Earned $225 million in milestones from Sanofi and over $800 million in nondilutive capital from partnerships in 18 months, including a new Pfizer agreement with billions in potential future revenue.
  • Cost Efficiency:: Combined R&D and SG&A expenses dropped 42% (Q4 2025) and 53% (full-year 2025), with a target of $200 million or below by 2028, a 50% reduction from 2025.
  • Pipeline Progress:: Preclinical C. diff vaccine candidate targets a $2.5 billion U.S. market, with potential IND filings in 2026 and clinical trials as early as 2027.
  • 2026 Financial Outlook:: Guidance for adjusted revenue of $230–270 million, supported by Nuvaxovid sales, licensing, and royalties, with Sanofi’s global Nuvaxovid launch a key driver.

Financial Guidance and Outlook

Novavax expects to generate revenue from its existing partnerships, including royalties from marketed and partnered products, as well as upfront payments from new potential partnerships. The company is guiding to a non-GAAP combined R&D and SG&A expense of $325 million in 2026, and $225 million in 2027. For 2028, the company expects to achieve a combined R&D and SG&A expense of $200 million or below.

Valuation Metrics

Novavax's current valuation metrics indicate a P/E Ratio of 3.67, P/B Ratio of -12.65, and P/S Ratio of 1.45. The company's EV/EBITDA ratio stands at 3.32. With an ROE of -546.21%, the company's return on equity is negative, but the ROIC is 64.28%, indicating a strong return on invested capital.

Partnerships and Business Development

Novavax is making significant progress in its partnership strategy, with existing partnerships earning and receiving upfront and milestone payments. The company has announced a new agreement with Pfizer for Matrix-M, which could generate billions of dollars of revenue over time. As Elaine O'Hara, Chief Strategy Officer, mentioned, "We're seeing that once vaccine-focused companies experiment with our adjuvant, they often come back to us to explore more broadly after seeing results from their initial experiments."

Pipeline Progress and R&D Efforts

Novavax is making steady progress in its R&D efforts, with a focus on expanding its Matrix technology platform. The company is advancing multiple programs, including C. diff, VZV, RSV triple combination, and new Matrix-based adjuvants. Ruxandra Draghia-Akli, Chief Research and Development Officer, stated that the company is "generating interesting results in the preclinical space and look forward to sharing data from other programs in the future."

Conclusion on Future Prospects

With a strong financial performance, a robust partnership strategy, and significant progress in its R&D efforts, Novavax is well-positioned for future growth. Analysts estimate a revenue decline of 36.3% for the next year, but the company's lean investments and focus on business development are expected to drive value creation. As John Jacobs, CEO, mentioned, "We're excited about our progress, but we'll be cautious about sharing details to maintain a competitive edge."

3. NewsRoom

Card image cap

Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of “Hold” from Analysts

Apr -13

Source: defenseworld.net

Card image cap

Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

Apr -09

Source: zacks.com

Card image cap

Novavax Faces Shareholder Revolt As Shah Capital Criticizes Strategy

Apr -08

Source: benzinga.com

Card image cap

Shah Capital intends to vote against Novavax's board nominees, executive compensation

Apr -08

Source: reuters.com

Card image cap

Traders Purchase Large Volume of Novavax Call Options (NASDAQ:NVAX)

Apr -07

Source: defenseworld.net

Card image cap

Novavax (NVAX) Stock Dips While Market Gains: Key Facts

Apr -01

Source: zacks.com

Card image cap

Novavax (NASDAQ:NVAX) Stock Price Passes Above 200 Day Moving Average – Here’s Why

Mar -31

Source: defenseworld.net

Card image cap

3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next

Mar -30

Source: 247wallst.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.47%)

6. Segments

Innovative Vaccines

Expected Growth: 10.47%

Novavax's 10.47% growth driven by increasing demand for innovative vaccines, successful clinical trials, and strategic partnerships. Strong pipeline of vaccine candidates, including COVID-19 and influenza vaccines, fuels growth. Government stockpiling and procurement agreements, as well as expanding global distribution network, contribute to revenue growth.

7. Detailed Products

NanoFlu

A nanoparticle-based quadrivalent influenza vaccine candidate

NVX-CoV2373

A recombinant spike protein-based COVID-19 vaccine candidate

ResVax

A respiratory syncytial virus (RSV) fusion protein nanoparticle vaccine candidate

NanoFlu-H1N1

A nanoparticle-based H1N1 influenza vaccine candidate

V114

A pneumococcal conjugate vaccine candidate

8. Novavax, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Novavax, Inc. faces moderate threat from substitutes due to the presence of established players in the vaccine development market. However, the company's focus on innovative vaccine technologies and its strong pipeline of products may help mitigate this threat.

Bargaining Power Of Customers

Novavax, Inc. has a diverse customer base, including governments, NGOs, and private organizations, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to public health, giving it an upper hand in negotiations.

Bargaining Power Of Suppliers

Novavax, Inc. relies on a network of suppliers for raw materials, equipment, and services. While the company has some bargaining power due to its size and reputation, suppliers may still exert some pressure on prices and delivery terms.

Threat Of New Entrants

The vaccine development market is highly competitive, and new entrants may pose a significant threat to Novavax, Inc. The company's strong intellectual property portfolio and established relationships with customers and partners may help deter new entrants, but the threat remains.

Intensity Of Rivalry

The vaccine development market is highly competitive, with several established players vying for market share. Novavax, Inc. faces intense rivalry from companies like Pfizer, Merck, and GSK, which may lead to pricing pressures and increased marketing expenses.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight -37.66%
Debt Cost 5.12%
Equity Weight 137.66%
Equity Cost 12.02%
WACC 14.62%
Leverage -27.36%

11. Quality Control: Novavax, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Royalty Pharma

A-Score: 6.4/10

Value: 4.7

Growth: 3.8

Quality: 7.4

Yield: 4.0

Momentum: 9.5

Volatility: 9.0

1-Year Total Return ->

View Full Report
Stock-Card
Exelixis

A-Score: 5.9/10

Value: 4.1

Growth: 8.0

Quality: 9.4

Yield: 0.0

Momentum: 8.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Novavax

A-Score: 4.7/10

Value: 9.4

Growth: 5.4

Quality: 8.5

Yield: 0.0

Momentum: 3.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Corcept Therapeutics

A-Score: 4.6/10

Value: 0.0

Growth: 7.8

Quality: 8.4

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Arcellx

A-Score: 4.2/10

Value: 6.2

Growth: 5.8

Quality: 5.0

Yield: 0.0

Momentum: 4.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Alpine Immune Sciences

A-Score: 4.0/10

Value: 6.0

Growth: 6.6

Quality: 4.2

Yield: 0.0

Momentum: 6.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

8.69$

Current Price

8.69$

Potential

-0.00%

Expected Cash-Flows